mp.weixin.qq.com·· 7 days agoScore59
CHMP Backs EU Approval of Revolution Medicines' Daraxonrasib for Metastatic Pancreatic Cancer
In brief
The EU's CHMP has issued a positive opinion recommending approval of Revolution Medicines' RASONQUE (daraxonrasib, RMC-6236) for metastatic pancreatic ductal adenocarcinoma. If the European Commission follows the recommendation, daraxonrasib would be approved across the EU for this indication. The opinion is dated 16 October 2026.
Source: mp.weixin.qq.com · mp.weixin.qq.com